Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Observational 1

Sponsor

Conditions

Breast Neoplasms 2Stomach Neoplasms 1Recurrent Squamous Cell Lung Carcinoma 1Neoplasms 1Multiple Myeloma 1Lymphoma 1Hematologic Neoplasms 1FGFR1 Gene Amplification 1Carcinoma, Non-Small-Cell Lung 1

Interventions

durvalumab 3Immunoglobulin G 3Disulfides 3tremelimumab 2Nivolumab 2Ipilimumab 2Docetaxel 2CTLA-4 Antigen 22-(3-(2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo(f)imidazo(1,2-d)(1,4)oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanamide 2telisotuzumab vedotin 1talazoparib 1rilotumumab 1palbociclib 1Erlotinib Hydrochloride 1AZD4547 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Recurrent Squamous Cell Lung Carcinoma × AZD4547 × Clear all
NCT02154490 2023-06-01

Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer

SWOG Cancer Research Network

Completed
1,864 enrolled 12 charts

Recurrent Squamous Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡